Product Description
Ondansetron is one of the medications most commonly used for empiric treatment of nausea and vomiting. Ondansetron has extreme utility as an antiemetic drug, and it is effective against nausea and vomiting of various etiologies. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/29763014/)
Mechanisms of Action: 5-HT3 Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous, Oral
FDA Designation: *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: GSK
Company Location: Europe
Company Founding Year: 2000
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Austria, Belgium, China, France, Italy, Poland, Spain, United States
Active Clinical Trial Count: 4
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Acute Pain|Morphine Dependence|Pain, Postoperative
Phase 2: Alzheimer Disease|Fallopian Tube Cancer|Other|Ovarian Cancer|Peritoneal Cancer
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
2022-502983-19-00 |
ZNâc3-005 | P2 |
Recruiting |
Fallopian Tube Cancer|Ovarian Cancer|Peritoneal Cancer |
2027-09-01 |
2025-05-02 |
Treatments |
|
2024-518523-30-00 |
ADVANCE-AD04-001 | P2 |
Recruiting |
Alzheimer Disease |
2026-12-31 |
2025-05-02 |
Treatments |
|
NCT04606264 |
STUDY19030022 | P3 |
Completed |
Morphine Dependence|Pain, Postoperative|Acute Pain |
2025-03-21 |
2025-10-23 |
||
CTR20170613 |
CTR20170613 | P2 |
Recruiting |
Other |
None |
2025-04-29 |
Patient Enrollment|Treatments|Trial Status |